CASI Pharmaceuticals Inc.

2.13
0.02 (0.95%)
At close: Apr 03, 2025, 3:58 PM
2.20
3.53%
After-hours: Apr 03, 2025, 06:14 PM EDT

CASI Pharmaceuticals Statistics

Share Statistics

CASI Pharmaceuticals has 13.4M shares outstanding. The number of shares has increased by 0% in one year.

Shares Outstanding 13.4M
Shares Change (YoY) 0%
Shares Change (QoQ) 0%
Owned by Institutions (%) 11.14%
Shares Floating 4.77M
Failed to Deliver (FTD) Shares 243
FTD / Avg. Volume 1.59%

Short Selling Information

The latest short interest is 75.57K, so 0.56% of the outstanding shares have been sold short.

Short Interest 75.57K
Short % of Shares Out 0.56%
Short % of Float 1.97%
Short Ratio (days to cover) 2.36

Valuation Ratios

The PE ratio is -3.55 and the forward PE ratio is -1.16. CASI Pharmaceuticals's PEG ratio is 0.12.

PE Ratio -3.55
Forward PE -1.16
PS Ratio 2.82
Forward PS 0.3
PB Ratio 3.96
P/FCF Ratio -4.31
PEG Ratio 0.12
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for CASI Pharmaceuticals.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 3.55, with a Debt / Equity ratio of 0.88.

Current Ratio 3.55
Quick Ratio 2.6
Debt / Equity 0.88
Debt / EBITDA -0.99
Debt / FCF -0.96
Interest Coverage 0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $192.49K
Profits Per Employee $-153.06K
Employee Count 176
Asset Turnover 0.45
Inventory Turnover 0.87

Taxes

Income Tax -81K
Effective Tax Rate 0.31%

Stock Price Statistics

The stock price has increased by -32.11% in the last 52 weeks. The beta is 0.61, so CASI Pharmaceuticals's price volatility has been higher than the market average.

Beta 0.61
52-Week Price Change -32.11%
50-Day Moving Average 2.36
200-Day Moving Average 4.53
Relative Strength Index (RSI) 42.87
Average Volume (20 Days) 15.25K

Income Statement

In the last 12 months, CASI Pharmaceuticals had revenue of 33.88M and earned -26.94M in profits. Earnings per share was -2.02.

Revenue 33.88M
Gross Profit 20.05M
Operating Income -25.08M
Net Income -26.94M
EBITDA -21.54M
EBIT -25.28M
Earnings Per Share (EPS) -2.02
Full Income Statement

Balance Sheet

The company has 17.08M in cash and 21.24M in debt, giving a net cash position of -4.16M.

Cash & Cash Equivalents 17.08M
Total Debt 21.24M
Net Cash -4.16M
Retained Earnings -660.82M
Total Assets 63.62M
Working Capital 32.41M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -19.97M and capital expenditures -2.24M, giving a free cash flow of -22.21M.

Operating Cash Flow -19.97M
Capital Expenditures -2.24M
Free Cash Flow -22.21M
FCF Per Share -1.66
Full Cash Flow Statement

Margins

Gross margin is 59.19%, with operating and profit margins of -74.03% and -79.51%.

Gross Margin 59.19%
Operating Margin -74.03%
Pretax Margin -77.61%
Profit Margin -79.51%
EBITDA Margin -63.58%
EBIT Margin -74.03%
FCF Margin -65.55%

Dividends & Yields

CASI does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for CASI is $6, which is 170.3% higher than the current price. The consensus rating is "Buy".

Price Target $6
Price Target Difference 170.3%
Analyst Consensus Buy
Analyst Count 1
Stock Forecasts

Stock Splits

The last stock split was on Jun 2, 2022. It was a backward split with a ratio of 1:10.

Last Split Date Jun 2, 2022
Split Type backward
Split Ratio 1:10

Scores

Altman Z-Score -15.36
Piotroski F-Score 1